Cargando…
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
Autores principales: | Rusconi, S, Vitiello, P, Adorni, F, Colella, E, Focà, E, Capetti, AF, Meraviglia, P, Abeli, C, Bonora, S, D'Annunzio, M, Di Biagio, A, Di Pietro, A, Butini, L, Orofino, G, Farina, S, d'Ettorre, G, Francisci, D, Soria, A, Buonomini, AR, Tommasi, C, Trotta, MP, Capasso, M, Merlini, E, Marchetti, GC |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112859/ http://dx.doi.org/10.1186/1758-2652-13-S4-O44 |
Ejemplares similares
-
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
por: Rusconi, Stefano, et al.
Publicado: (2013) -
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014) -
Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012) -
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019) -
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)